Development of nanotherapeutics for the treatment of glioblastoma
Glioblastoma (GBM) is the most malignant form of brain tumor. Patients die from relapse of the tumor after surgery, radiotherapy and chemotherapy. Current treatments for GBM have very low efficacy due to their incapacity to cross the blood-brain barrier (BBB) and to eliminate resilient cancers stem cells.
The goal of this highly interdisciplinary project is to develop nanotherapeutics capable of overcoming the BBB and of eliminating all tumor cells, including cancer stem cells. We are interested in developing ligands to target the nanocarrier systems and to cross the BBB. We also aim to engineer polymeric coatings to enhance the stability of the nanocarriers for gene delivery will also be engineered.
This project is funded by the European Commission (MSCA-844441).
Generation of environmentally sensitive antibodies
We are working on the development of stimulus-responsive antibodies to enhance the selectivity of nanotherapeutics.
Phage display engineering
We aim to develop new peptide and protein therapeutics by expanding the chemical diversity encoded into phage displayed molecules.